engleski

Initial clinical experience with brinzolamid 1% ophthalmic suspension (Azopt)

The aim of this study was to assess the intraocular hypotensive effect of 1% brinzolamide as monotherapy in patients with primary and secondary glaucoma.The six months study included 20 patients of which 19 completed the study.All patients had prevously received local antiglaucoma therapy.Resulst of this study suggested monotherapy with 1.0% brinzolamid to be successful in the regulation of intraocular pressure in patients with primary or secundary glaucoma

carbonic anhydrase inhibitors; glaucoma drug therapy

nije evidentirano